Ask AI
ProCE Banner Activity

Treating Multiple Myeloma When T-Cell Redirection Is Not an Option

Video

Dr Joshua Richter reviews multiple myeloma treatment options for patients who are ineligible for or decline T-cell redirection therapy, including CAR T-cell therapy and bispecific antibodies. He discusses alternative therapies for relapsed or refractory multiple myeloma, including belantamab mafodotin, selinexor, venetoclax, cytotoxic chemotherapy, and emerging CELMoDs, with a focus on treatment sequencing, efficacy, and toxicity.

Released: July 30, 2026